Trial · NCT00174941
Adverse events192
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 192
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Febuxostat 40 mg QD | 0 | 12 | |
| other | Diarrhoea | Gastrointestinal disorders | Febuxostat 80 mg QD | 9 | 116 | |
| other | Diarrhoea | Gastrointestinal disorders | Febuxostat 120 mg QD | 1 | 37 | |
| other | Diarrhoea | Gastrointestinal disorders | Febuxostat Total | 10 | 116 | |
| other | Liver Function Analyses | Investigations | Febuxostat 40 mg QD | 0 | 12 | |
| other | Liver Function Analyses | Investigations | Febuxostat 80 mg QD | 4 | 116 | |
| other | Liver Function Analyses | Investigations | Febuxostat 120 mg QD | 2 | 37 | |
| other | Liver Function Analyses | Investigations | Febuxostat Total | 6 | 116 | |
| other | Gastrointestinal Atonic and Hypomotility Disorders NEC | Gastrointestinal disorders | Febuxostat 40 mg QD | 0 | 12 | |
| other | Gastrointestinal Atonic and Hypomotility Disorders NEC | Gastrointestinal disorders | Febuxostat 80 mg QD | 5 | 116 | |
| other | Gastrointestinal Atonic and Hypomotility Disorders NEC | Gastrointestinal disorders | Febuxostat 120 mg QD | 0 | 37 | |
| other | Gastrointestinal Atonic and Hypomotility Disorders NEC | Gastrointestinal disorders | Febuxostat Total | 5 | 116 | |
| other | Headaches NEC | Nervous system disorders | Febuxostat 40 mg QD | 0 | 12 | |
| other | Headaches NEC | Nervous system disorders | Febuxostat 80 mg QD | 5 | 116 | |
| other | Headaches NEC | Nervous system disorders | Febuxostat 120 mg QD | 0 | 37 | |
| other | Headaches NEC | Nervous system disorders | Febuxostat Total | 5 | 116 | |
| other | Hyperlipidaemias NEC | Metabolism and nutrition disorders | Febuxostat 40 mg QD | 1 | 12 | |
| other | Hyperlipidaemias NEC | Metabolism and nutrition disorders | Febuxostat 80 mg QD | 3 | 116 | |
| other | Hyperlipidaemias NEC | Metabolism and nutrition disorders | Febuxostat 120 mg QD | 0 | 37 | |
| other | Hyperlipidaemias NEC | Metabolism and nutrition disorders | Febuxostat Total | 4 | 116 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00174941/events